Latest market price
50.39
-0.18-0.36%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.49 | Insider Own | 2.46% | Shs Outstand | 94.26M | Perf Week | 0.62% |
| Market Cap | 4.75B | Forward P/E | 17.61 | EPS next Y | 2.86 | Insider Trans | -60.86% | Shs Float | 91.48M | Perf Month | -11.36% |
| Enterprise Value | 4.88B | PEG | — | EPS next Q | — | Short Float | 11.93% | Perf Quarter | -8.35% | ||
| Income | -43.00M | P/S | 8.02 | EPS this Y | — | Short Ratio | 6.67 | Perf Half Y | 14.21% | ||
| Sales | 592.00M | P/B | 190.01 | EPS next Y | — | ROA | -5.44% | Short Interest | 10.91M | Perf YTD | 31.88% |
| Book/sh | 0.27 | P/C | 9.71 | EPS next 5Y | — | ROE | -55.79% | 52W High | 68.73 -26.68% | Perf Year | 68.08% |
| Cash/sh | 5.19 | P/FCF | 93.13 | EPS past 3/5Y | — | ROIC | -6.19% | 52W Low | 22.59 123.06% | Perf 3Y | 622.96% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 65.15% 19.92% | Gross Margin | 94.41% | Volatility | 4.11% 4.18% | Perf 5Y | 91.74% |
| Dividend TTM | — | EV/Sales | 8.24 | EPS Y/Y TTM | — | Oper. Margin | -6.84% | ATR (14) | 2.28 | Perf 10Y | 146.89% |
| Dividend Ex-Date | — | Quick Ratio | 3.99 | Sales Y/Y TTM | 77.25% | Profit Margin | -7.35% | RSI (14) | 35.44 | Recom | 2.17 |
| Dividend Gr. 3/5Y | — | Current Ratio | 4.05 | EPS Q/Q | -164.29% | SMA20 | -3.22% | Beta | 1.09 | Target Price | 76.00 |
| Payout | 0.00% | Debt/Eq | 24.68 | Sales Q/Q | 49.12% | SMA50 | -14.68% | Rel Volume | 0.64 | Prev Close | 50.57 |
| Employees | 497 | LT Debt/Eq | 24.44 | Earnings | Nov 02 | SMA200 | 8.09% | Avg Volume | 1.77M | Price | 50.39 |
| IPO Date | Nov 08, 2012 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -174.79% 7.83% | Net Debt/EBITDA | 25.60 | Volume | 1,126,085 | Change | -0.36% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-24-26 | Reiterated | Guggenheim | Buy | $65 → $89 |
| Aug-10-26 | Reiterated | Evercore ISI Group | Outperform | $33 → $78 |
| Aug-06-26 | Reiterated | Canaccord Genuity | Buy | $23 → $70 |
| Jun-25-26 | Reiterated | Guggenheim | Buy | $54 → $65 |
| Jun-02-26 | Reiterated | HC Wainwright & Co. | Buy | $18 → $67 |
| Apr-14-26 | Reiterated | Piper Sandler | Neutral | $12 → $49 |
| Apr-14-26 | Reiterated | Guggenheim | Buy | $49 → $54 |
| Jan-14-26 | Reiterated | Guggenheim | Buy | $23 → $49 |
| Sep-10-25 | Reiterated | Jefferies | $35 | |
| Oct-31-24 | Reiterated | Evercore ISI | Outperform | $30 → $33 |
Latest News· Times ET
Oct-28-26
Oct-26-26
Oct-23-26
Oct-23-2607:20PM
Oct-22-26
Oct-22-2611:01AM
Oct-13-26
Oct-13-2607:03AM
Oct-12-26
Oct-12-2605:00PM
Oct-07-26
Oct-07-2602:10AM
Oct-02-26
Oct-02-2610:00AM
Sep-30-26
Sep-30-2609:58AM
Sep-24-26
Sep-23-26
Sep-23-2608:00AM
Sep-21-26
Sep-21-2604:05PM
Company
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 592 | 491 | 233 | 145 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 34 | 10 | 8 | 11 | — | — | — | — | — | |
| Gross Profit | 557 | 480 | 225 | 134 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 364 | 337 | 264 | 266 | — | — | — | — | — | |
| Research and Development | 227 | 206 | 283 | 245 | — | — | — | — | — | |
| Other Operating Expense | 7 | 0 | 2 | 11 | — | — | — | — | — | |
| Operating Income | -40 | -63 | -324 | -388 | — | — | — | — | — | |
| Interest Expense | 9 | 11 | 11 | 11 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -17 | 24 | 14 | 23 | — | — | — | — | — | |
| Net Income Before Taxes | -67 | -49 | -321 | -376 | — | — | — | — | — | |
| Income Taxes | 1 | 1 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -43 | -26 | -322 | -111 | — | — | — | — | — | |
| Net Income From Continuing Operations | -68 | -50 | -321 | -376 | — | — | — | — | — | |
| Net Income | -43 | -26 | -322 | -111 | — | — | — | — | — | |
| EPS (Recurring) | -0.45 | -0.56 | -4.08 | -1.50 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.45 | -0.56 | -4.08 | -1.50 | — | — | — | — | — | |
| EPS (Diluted) | -0.49 | -0.56 | -4.08 | -1.50 | — | — | — | — | — | |
| EBITDA | 5 | 22 | -266 | -326 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 7.92 | 6.93 | 5.91 | 4.59 | — | — | — | — | — | |
| Gross Margin | 94.09 | 97.76 | 96.57 | 92.41 | — | — | — | — | — | |
| Operating Margin | -6.76 | -12.83 | -139.06 | -267.59 | — | — | — | — | — | |
| Net Margin | -7.26 | -5.30 | -138.20 | -76.55 | — | — | — | — | — | |
| Shares Outstanding | 93 | 89 | 79 | 74 | — | — | — | — | — | |
| Market Capitalization | 4,686 | 3,401 | 1,376 | 665 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Oct 15 '26 | Sale | 53.82 | 243,735 | 13,116,670 | 432,886 | Oct 19 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Oct 15 '26 | Option Exercise | 12.15 | 243,735 | 2,961,597 | 676,621 | Oct 19 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sep 17 '26 | Option Exercise | 23.34 | 108,493 | 2,532,227 | 541,379 | Sep 17 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sep 17 '26 | Sale | 65.07 | 8,282 | 538,917 | 117,066 | Sep 17 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sep 17 '26 | Option Exercise | 22.40 | 8,282 | 185,517 | 125,348 | Sep 17 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sep 17 '26 | Sale | 64.61 | 108,493 | 7,009,671 | 432,886 | Sep 17 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sep 16 '26 | Sale | 63.43 | 172,717 | 10,956,088 | 117,066 | Sep 17 |
| ROTE WILLIAM E. | Chief Research Officer | Sep 16 '26 | Option Exercise | 21.29 | 112,850 | 2,402,186 | 211,047 | Sep 17 |
| ROTE WILLIAM E. | Chief Research Officer | Sep 16 '26 | Sale | 63.33 | 112,850 | 7,146,644 | 98,197 | Sep 17 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sep 16 '26 | Option Exercise | 14.19 | 172,717 | 2,451,533 | 289,783 | Sep 17 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sep 16 '26 | Option Exercise | 23.34 | 195,841 | 4,570,929 | 628,727 | Sep 17 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sep 16 '26 | Sale | 63.45 | 195,841 | 12,425,253 | 432,886 | Sep 17 |
| REED ELIZABETH E | Chief Legal Officer and GC | Sep 15 '26 | Sale | 62.34 | 37,500 | 2,337,695 | 105,389 | Sep 17 |
| ROTE WILLIAM E. | Chief Research Officer | Sep 15 '26 | Sale | 62.25 | 96,198 | 5,988,754 | 98,197 | Sep 17 |
| Heerma Peter | EVP, CHIEF COMMERCIAL OFFICER | Sep 15 '26 | Sale | 62.26 | 102,190 | 6,362,825 | 117,066 | Sep 17 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.